As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.
MarketsandMarkets are proud to host its inaugural “qPCR and dPCR Virtual Conference” which will be held on 15th - 16th April 2021. The conference will focus on the latest developments in digital and real time PCR and also, its application in cancer diagnosis and infectious disease diagnostics.
CEO, Colby Pharmaceuticals, USA
Research Director, CNRS, INSERM, France
Thematic Coordinator, Molecular Diagnostics, AIT Austrian Institute of Technology, Austria
Faculty of Medicine and Health Sciences, Ghent University, Europe
Chief Scientific Officer, DiaCarta, USA
Head Business Development, INVITEK Molecular, Germany
Co-Founder, Scope Fluidics, Poland
Eawag, Switzerland, Group Leader in the Department of Environmental Microbiology
Director of Molecular Biology R&D, Stilla Technologies, France